Third-Quarter Reported Diluted EPS grew 49.2% to $1.97, Adjusted Diluted EPS increased by 14.4% to $1.91 and grew by 18.0% excluding currency

STAMFORD, CT--(BUSINESS WIRE)--Oct. 22, 2024-- Regulatory News:

Philip Morris International Inc. (PMI) (NYSE: PM) today announces its 2024 third-quarter and first nine-months results.1

“In the third quarter, we delivered exceptionally strong performance, with record quarterly net revenues and earnings per share,” said Jacek Olczak, Chief Executive Officer.
“This reflects excellent momentum across all regions and categories, with a reacceleration in IQOS adjusted in-market sales growth, strong ZYN volumes, and resilient combustible performance.” 
“As a result of our strong year-to-date delivery, we are raising our full-year growth outlook for adjusted diluted EPS to a range of 14% to 15%, excluding currency.”

Third Quarter Highlights

  • Smoke-free business (SFB): Quarterly shipments of smoke-free products (SFP), available in 92 markets, reached close to 40 billion units. The smoke-free business accounted for 38% of our total net revenues and 40% of gross profit (up by 1.9pp and 2.2pp respectively, versus third-quarter last year), and continues to deliver superior performance, with net revenues increasing by 14.2% (16.8% organically) and gross profit increasing by 15.9% (20.2% organically).
  • Inhalable smoke-free products: IQOS continues strengthening its overall position as the second largest nicotine ‘brand’ in markets where present (gaining 1.0pp of combined cigarette and HTU industry volumes) and driving the growth of the heat-not-burn category (reaching nearly 77% of global category volumes). HTU adjusted in-market sales (IMS) volume, which excludes the net impact of estimated distributor and wholesaler inventory movements, was up by an estimated 14.8%.
    • In Japan, ILUMA i fueled the growth of IQOS, with adjusted IMS up by 14.3%, the 8th consecutive quarter of double-digit growth. IQOS HTU adjusted market share increased by 3.2pp to nearly 30%, driving the overall category to at least 50% of total nicotine offtake share in 8 major cites, including Tokyo and Yokohama.
    • In Europe, IQOS HTU adjusted market share increased by 0.8pp to 9.5%. Adjusted IMS growth reaccelerated to 11.3%, with Italy recovering well and 8 markets growing in excess of 20%, including Greece and Germany. Our portfolio of IQOS consumables continues to expand with both DELIA and LEVIA now being available in 9 markets each, with further launches planned in Q4.
    • Outside Europe and Japan, adjusted IMS growth accelerated and we grew offtake share in key cities across the globe, including Seoul, Toronto, Mexico City, Cairo, and Jakarta. Our strong growth in Indonesia benefits from the expansion of our geographic reach and consumables portfolio, with premium clove and capsule products.

In the vaping category, our focused strategy is delivering good results with excellent volume momentum and unit cost improvements. Europe is at the forefront, as the closed pod segment continues to take share from disposables. VEEV continues to lead the closed pod segment in several markets, including Italy, Romania, and the Czech Republic.

  • Oral SFP2Shipment volume increased by 24.7% in cans (22.2% in pouches or pouch equivalents), fueled by ZYN nicotine pouch growth in the U.S., where shipments reached 149.1 million cans, representing growth of 41.4% versus prior year as supply constraints start to ease. Outside the U.S., our nicotine pouch volume in cans grew by nearly 70%, with notable contributions from Pakistan and South Africa. The number of markets with ZYN presence increased to 30, including recent launches in Greece and Czech Republic.
  • Combustibles: Net revenues grew by 5.2% (8.6% organically), driven by another quarter of high single-digit pricing and resilient industry volumes. Both our global brands portfolio and Marlboro achieved their highest quarterly market shares since the 2008 spin-off.
  • Dividend: Increased regular quarterly dividend by 3.8% to $1.35 per share, or an annualized $5.40 per share.

Source:https://www.pmi.com/media-center/press-releases/press-details/?newsId=28126

电子雾化与HNB产品都是新型电子产品,结构虽小,却融合应用多种材料、表面处理、芯片电子等技术工艺,而且雾化技术一直在不断更迭,供应链在逐步完善,为了促进供应链企业间有一个良好的对接交流,艾邦搭建产业微信群交流平台,欢迎加入;Vape e-cigarettes (VAPE) and Heat-Not-Burn e-cigarettes (HNB) are both emerging electronic products. Despite their compact size, they integrate various materials, surface treatment technologies, chip electronics, and other advanced technical processes. Moreover, atomization technology is constantly evolving and the supply chain is being progressively perfected. To facilitate good communication and networking among supply chain enterprises, Aibang has established an industry WeChat group communication platform and warmly welcomes interested enterprises to join.

资料下载:
通讯录:
Vape 加热不燃烧 低温本草 草本雾化 CBD 品牌 成品工厂 渠道商 物流 贸易 雾化芯 发热丝 陶瓷雾化芯 发热片 成品雾化芯 雾化器 烟嘴 烟油 香精 储油棉 玻纤管 纸管 降温段 SMT 方案商 方案设计 咪头 电芯 电池 mcu 芯片 mos管 PCB 显示屏 pin针 磁铁 线材 马达 电子元件 连接器 工业设计 防伪 塑胶件 塑料 原材料 PCTG 透明尼龙 PPSU PEEK 硅橡胶 密封件 注塑 模具 模具设计 表面处理 IMD/IML 五金 铝管 不锈钢管 压铸 铝外壳 铝挤 玻璃仓 外观件 3D玻璃 包装 厚膜印刷设备 注塑机 自动化设备 整线 烟弹组装 包棉机 注油机 压盖机 包装设备 贴标机 认证 检测 检测设备 激光设备 烧结炉 加工设备 设备配件 加工耗材 充电器 实体店 评测 自动售货机 媒体 医用雾化器 电子产品 其他

作者 xie, yao

zh_CNChinese